Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 4/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | GPR55 | Q9Y2T6 | 2/20 | 0.35 |
| ▸ | JAK2 | O60674 | 2/20 | 0.35 |
| ▸ | JAK3 | P52333 | 2/20 | 0.35 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 7/20 | 0.34 |
| ▸ | ESR1 | P03372 | 2/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.33 |
| ▸ | PDE5A | O76074 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29393664 | 1.00 | SLC6A9 (0.35) | SLC6A9DRD2DRD3GPR55JAK2 | |
| SCHEMBL26072390 | 0.89 | SLC6A9 (0.35) | SLC6A9DRD2DRD3GPR55JAK2 | |
| SCHEMBL29393689 | 0.89 | SLC6A9 (0.35) | SLC6A9DRD2DRD3GPR55JAK2 | |
| SCHEMBL26072270 | 0.88 | JAK2 (0.34) | SLC6A9GPR55JAK2JAK3PTK2 | |
| SCHEMBL26072099 | 0.84 | JAK2 (0.39) | DRD2JAK2JAK3PTK2PTGS2 | |
| SCHEMBL29394099 | 0.84 | JAK2 (0.39) | DRD2JAK2JAK3PTK2PTGS2 | |
| SCHEMBL29393647 | 0.84 | SYK (0.39) | SLC6A9GPR55JAK2JAK3PTK2 | |
| SCHEMBL26072045 | 0.84 | SYK (0.39) | SLC6A9GPR55JAK2JAK3PTK2 | |
| SCHEMBL26381110 | 0.84 | SLC6A9 (0.35) | SLC6A9DRD2DRD3GPR55JAK2 | |
| SCHEMBL26071927 | 0.81 | JAK3 (0.34) | SLC6A9JAK2JAK3PTK2PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312565-A1 | 1H-PYRROLO[3,2-C]PYRIDINE AND 1H-PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS | BRISTOL MYERS SQUIBB CO (US) | 2023-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312565-A1 | 1H-PYRROLO[3,2-C]PYRIDINE AND 1H-PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS | TLR9, TLR1, TLR7 | SLC6A9 3650/4885DRD2 4065/4885DRD3 3926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.